Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
S. W. Quist, A. J. Postma, K. J. Myrén, L. A. de Jong, M. J. Postma
Year of publication: |
2023
|
---|---|
Authors: | Quist, S. W. ; Postma, A. J. ; Myrén, K. J. ; de Jong, L. A. ; Postma, M. J. |
Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 24.2023, 9, p. 1455-1472
|
Subject: | Cost–benefit analysis | C5-inhibitors | Costs and cost analysis | Eculizumab | Hemoglobinuria | Paroxysmal | Ravulizumab | Niederlande | Netherlands | Kosten-Nutzen-Analyse | Cost-benefit analysis | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Gesundheitskosten | Health care costs |
Saved in:
freely available
Saved in favorites
Similar items by subject
-
The science of making better decisions about health : cost-effectiveness and cost-benefit analysis
Russell, Louise, (2014)
-
Cost effectiveness and payment policy
Garber, Alan M., (2012)
-
Costs of hospital care for strokes in India : a scoping review
Benedetto, Valerio, (2023)
- More ...